These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36857968)

  • 21. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial.
    Gonzales MM; Garbarino VR; Marques Zilli E; Petersen RC; Kirkland JL; Tchkonia T; Musi N; Seshadri S; Craft S; Orr ME
    J Prev Alzheimers Dis; 2022; 9(1):22-29. PubMed ID: 35098970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial.
    Hailong Z; Jiansheng L; Wen G; Lu W; Dong Z; Limin Z; Miao Z; Weixian L
    Trials; 2022 Feb; 23(1):103. PubMed ID: 35109889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Naccache JM; Jouneau S; Didier M; Borie R; Cachanado M; Bourdin A; Reynaud-Gaubert M; Bonniaud P; Israël-Biet D; Prévot G; Hirschi S; Lebargy F; Marchand-Adam S; Bautin N; Traclet J; Gomez E; Leroy S; Gagnadoux F; Rivière F; Bergot E; Gondouin A; Blanchard E; Parrot A; Blanc FX; Chabrol A; Dominique S; Gibelin A; Tazi A; Berard L; Brillet PY; Debray MP; Rousseau A; Kerjouan M; Freynet O; Dombret MC; Gamez AS; Nieves A; Beltramo G; Pastré J; Le Borgne-Krams A; Dégot T; Launois C; Plantier L; Wémeau-Stervinou L; Cadranel J; Chenivesse C; Valeyre D; Crestani B; Cottin V; Simon T; Nunes H;
    Lancet Respir Med; 2022 Jan; 10(1):26-34. PubMed ID: 34506761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
    Daniels CE; Lasky JA; Limper AH; Mieras K; Gabor E; Schroeder DR;
    Am J Respir Crit Care Med; 2010 Mar; 181(6):604-10. PubMed ID: 20007927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.
    Raghu G; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Burgess T; Kamath N; Donaldson F; Richeldi L
    Respir Res; 2022 May; 23(1):129. PubMed ID: 35597980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial.
    Guo S; Song Y; Feng J; Liu S; Li Y; Liu M; Wei L; Zhang X; Xie H; Sun Z
    J Tradit Chin Med; 2020 Aug; 40(4):674-682. PubMed ID: 32744035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular Senescence in Idiopathic Pulmonary Fibrosis.
    Kellogg DL; Kellogg DL; Musi N; Nambiar AM
    Curr Mol Biol Rep; 2021; 7(3):31-40. PubMed ID: 34401216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease.
    Gonzales MM; Garbarino VR; Kautz T; Palavicini JP; Lopez-Cruzan M; Dehkordi SK; Mathews J; Zare H; Xu P; Zhang B; Franklin C; Habes M; Craft S; Petersen RC; Tchkonia T; Kirkland J; Salardini A; Seshadri S; Musi N; Orr ME
    Res Sq; 2023 Apr; ():. PubMed ID: 37162971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial).
    Martinez FJ; Wijsenbeek MS; Raghu G; Flaherty KR; Maher TM; Wuyts WA; Kreuter M; Kolb M; Chambers DC; Fogarty C; Mogulkoc N; Tutuncu AS; Richeldi L
    Am J Respir Crit Care Med; 2022 May; 205(9):1084-1092. PubMed ID: 35050837
    [No Abstract]   [Full Text] [Related]  

  • 31. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
    Richeldi L; Fernández Pérez ER; Costabel U; Albera C; Lederer DJ; Flaherty KR; Ettinger N; Perez R; Scholand MB; Goldin J; Peony Yu KH; Neff T; Porter S; Zhong M; Gorina E; Kouchakji E; Raghu G
    Lancet Respir Med; 2020 Jan; 8(1):25-33. PubMed ID: 31575509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.
    Farr JN; Atkinson EJ; Achenbach SJ; Volkman TL; Tweed AJ; Vos SJ; Ruan M; Sfeir J; Drake MT; Saul D; Doolittle ML; Bancos I; Yu K; Tchkonia T; LeBrasseur NK; Kirkland JL; Monroe DG; Khosla S
    Nat Med; 2024 Sep; 30(9):2605-2612. PubMed ID: 38956196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase IIb Randomized Clinical Study of an Anti-α
    Raghu G; Mouded M; Chambers DC; Martinez FJ; Richeldi L; Lancaster LH; Hamblin MJ; Gibson KF; Rosas IO; Prasse A; Zhao G; Serenko M; Novikov N; McCurley A; Bansal P; Stebbins C; Arefayene M; Ibebunjo S; Violette SM; Gallagher D; Behr J
    Am J Respir Crit Care Med; 2022 Nov; 206(9):1128-1139. PubMed ID: 35771569
    [No Abstract]   [Full Text] [Related]  

  • 36. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.
    Maher TM; Simpson JK; Porter JC; Wilson FJ; Chan R; Eames R; Cui Y; Siederer S; Parry S; Kenny J; Slack RJ; Sahota J; Paul L; Saunders P; Molyneaux PL; Lukey PT; Rizzo G; Searle GE; Marshall RP; Saleem A; Kang'ombe AR; Fairman D; Fahy WA; Vahdati-Bolouri M
    Respir Res; 2020 Mar; 21(1):75. PubMed ID: 32216814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
    Yang SG; Yu XQ; Li JS; Xie Y; Zhang W; Ban C; Feng J; Wu L; Lu X; Zhao L; Meng Y; Zhou M; He Y; Luo W
    Trials; 2022 Sep; 23(1):725. PubMed ID: 36056382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.